Evidence map›Paper›PMID 38352040›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease.

Zitianyu Wang, Victoria Lewis, Christiane Stehmann, Shiji Varghese, Matteo Senesi, Amelia McGlade, Laura J Ellett, James D Doecke, Dhamidhu Eratne, Dennis Velakoulis and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Zitianyu WangNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.ORCID https://orcid.org/0009-0005-9375-8332
Victoria LewisAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute The University of Melbourne Parkville Australia.
Christiane StehmannAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute The University of Melbourne Parkville Australia.
Shiji VargheseNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.
Matteo SenesiAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute The University of Melbourne Parkville Australia.
Amelia McGladeAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute The University of Melbourne Parkville Australia.
Laura J EllettAustralian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute The University of Melbourne Parkville Australia.
James D DoeckeAustralian e-Health Research Centre CSIRO Parkville Australia.
Dhamidhu EratneNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.
Dennis VelakoulisNeuropsychiatry, John Cade Building Royal Melbourne Hospital Parkville Australia.
Colin L MastersNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.
Steven J CollinsNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.
Qiao-Xin LiNational Dementia Diagnostics Laboratory (NDDL), The Florey Institute The University of Melbourne Parkville Australia.
The University of Melbourne · AUThe Royal Melbourne Hospital · AUCommonwealth Scientific and Industrial Research Organisation · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most suspected Creutzfeldt-Jakob disease (CJD) cases are eventually diagnosed with other disorders. We assessed the utility of investigating Alzheimer's disease (AD) biomarkers and neurofilament light (NfL) in patients when CJD is suspected. The study cohort consisted of cerebrospinal fluid (CSF) samples referred for CJD biomarker screening wherein amyloid beta 1-42 (Aβ1-42), phosphorylated tau 181 (p-tau181), and total tau (t-tau) could be assessed via Elecsys immunoassays (

Indexed as

Alzheimer's diseaseamyloid beta 1‐42cerebrospinal fluid biomarkerCreutzfeldt‐Jakob diseasedifferential diagnosisElecsysneurofilament lightphosphorylated tau181rapidly progressive dementiatotal tau/phosphorylated tau181 ratio

Identifiers

PMID38352040
PMCPMC10862167
OpenAlexW4391789550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.